EP300 and acute myeloid leukemia: SE activation is highly sensitive to interference in occupancy of these coactivators13 and knockdown or pharmacological inhibition of p300, MED1 or BRD4 decommissions the activation status of SEs and leads to repression of associated target genes, including oncogenic drivers of AML cells20,28–31,52.